A Randomized Single Blind Study on the Improvement of Social Disability and Self-efficacy in Depressive Disorder by Solution Focused Group Therapy
-
摘要:
目的 焦点解决团体治疗(solution focused group therapy, SFGT)联合艾司西酞普兰治疗抑郁障碍的疗效评估。 方法 选取云南省精神病医院符合ICD-10抑郁障碍诊断标准的84例患者,随机分入联合42例和单一药物组42例,开展为期8周的治疗。采用精神病人生存质量问卷(social disability screening schedule, SDSS)和一般自我效能感量表(genera self-efficacy scale, GSES)进行效果评价,并使用SPSS22.0进行数据分析。 结果 8周治疗结束后, 2组共脱落18例,其中联合治疗组共脱落8例。对照组脱落10例, 2组在治疗前SDSS、GSES各分量表及总分均无差异,SDSS量表在治疗第4周、第8周量表总分及各分量表得分联合治疗均低于对照组,且具有统计学意义( P < 0.05)。联合治疗组的GSES评分在干预第4周及第8周均高于对照组,且差异具有统计学意义( P < 0.05)。 结论 焦点解决团体治疗(SFGT)联合艾司西酞普兰治疗抑郁障碍疗法比单一药物治疗疗效更好。 Abstract:Objective To focus on the difference between solution focused group therapy (SFGT) combined with Escitalopram and only use Escitalopram in the treatment of depression group, and evaluate the efficacy of focus resolution short-course group psychotherapy (SFGT) combined with Escitalopram in the treatment of depressive disorders. Methods Eithty-four patients who met the diagnostic criteria of ICD-10 depression in Yunnan Psychiatric Hospital were randomly divided into combined treatment group (42 patients) and simple drug group (42 patients). The period of this treatment was 8 weeks. A total of 84 patients who met the diagnostic criteria of ICD-10 depressive disorder in our hospital were randomly divided into combination therapy group and single drug group for 8 weeks of treatment. The effect was evaluated by Social Disability Screening Schedule (SDSS) and Genera Self-efficacy Scale (GSES), and SPSS22.0 was used for statistical analysis. Results After 8 weeks of treatment, 18 cases fell from the two groups, including 8 cases from the combined treatment group and 10 cases from the control group. There was no difference in the subscales and total scores of SDSS and GSES between the two groups before treatment. The total scores and subscales scores of SDSS were lower than those in the control group at the 4th and 8th weeks of treatment (P < 0.05) . Compared with the control group, the GSES scores of the combined treatment group were higher than those of the control group at the 4th and 8th week in the course of treatment, and the difference was statistically significant (P < 0.05). Conclusions Solution focused group therapy (SFGT) combined with Escitalopram is better than drug therapy alone in the treatment of depression. Solution focused group therapy (SFGT) combined with Ecitalopram is more effective than monotherapy for depressive disorders. -
表 1 联合治疗组和对照组抑郁发作患者均衡性检验[n(%)/M(P25,P75)/(
$ \bar x \pm s $ )]Table 1. Balance test of depression patients in combined treatment group and control group [n(%)/M(P25,P75)/(
$ \bar x \pm s $ )]变量 类别 联合治疗组(n = 34) 对照组(n = 32) t/Z/χ2 P 性别 0.073 0.787 男 18(52.9) 18(56.3) 女 16(47.1) 14(43.7) 年龄(岁) 37.06 ± 10.96 40.88 ± 10.47 1.022 0.315 婚姻 0.340 0.844 未婚 6(17.6) 6(18.8) 已婚 22(64.7) 22(68.8) 离异/丧偶 6(17.6) 4(12.5) 受教育程度 6.624 0.157 初中 4(11.8) 4(12.5) 高中 8(23.5) 12(37.5) 大专 4(11.8) 8(25.0) 本科 16(47.1) 6(18.8) 硕士及以上 2(5.9) 2(6.3) 病程(a) 3(1,12) 5.5(1.25,9.5) 0.365 0.715 发病次数 2(1,4) 3(1,4) 0.786 0.432 HAMD基础分 30.06 ± 4.42 27.69 ± 4.37 1.573 0.126 表 2 联合治疗组和对照组SDSS量表评分[(
$ \bar x \pm s $ ),分]Table 2. SDSS scale scores of combined treatment group and control group [(
$ \bar x \pm s $ ),scores]组别 SDSS评分 干预前 第4周 第8周 治疗组 生理 41.06 ± 8.30 28.85 ± 4.85 21.76 ± 3.75 对照组 39.07 ± 3.79 33.13 ± 5.11 29.12 ± 5.11 t 1.746 −2.584 −4.737 P 0.091 0.015* < 0.001** 治疗组 心理 41.29 ± 9.56 28.00 ± 4.64 22.64 ± 4.58 对照组 40.38 ± 5.32 32.56 ± 5.15 29.43 ± 5.24 t 0.997 −2.677 −3.969 P 0.327 0.012* < 0.001** 治疗组 社会 44.47 ± 9.92 34.53 ± 4.97 25.70 ± 5.24 对照组 43.44 ± 4.62 38.43 ± 3.95 35.93 ± 4.07 t 1.437 −2.344 −6.326 P 0.161 0.026* < 0.001** 治疗组 症状 16.29 ± 3.57 10.52 ± 2.18 8.54 ± 1.29 对照组 16.63 ± 2.45 12.43 ± 2.30 10.50 ± 2.28 t 0.596 −2.441 −2.432 P 0.556 0.021* 0.021* 治疗组 总分 143.12 ± 29.23 101.70 ± 11.97 79.58 ± 11.06 对照组 139.50 ± 13.32 116.56 ± 12.49 105.00 ± 11.92 t 1.592 −3.489 −6.350 P 0.122 0.001** < 0.001** * P < 0.05,**P < 0.01。 表 3 联合治疗组和对照组GSES量表评分[(
$ \bar x \pm s $ ),分]Table 3. GSES scale scores of combined treatment group and control group [(
$ \bar x \pm s $ ),scores]组别 干预前 第4周 第8周 治疗组 18.65 ± 4.37 26.00 ± 2.43 28.71 ± 2.23 对照组 19.38 ± 4.35 23.19 ± 4.04 25.69 ± 2.75 t −0.479 2.444 3.473 P 0.635 0.020* 0.002** *P < 0.05,**P < 0.01。 -
[1] 李凌江, 马辛. 中国抑郁障碍防治指南(第2版)[M]. 北京: 中华医学电子音像出版社, 2015: 87-90. [2] Cipriani A,Furukawa T A,Salanti G,et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder:a systematic review and network meta-analysis[J]. Lancet,2018,391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7 [3] 刘强,李洪超,马爱霞. 一线抗抑郁药临床疗效的网状Meta分析[J]. 中国药物评价,2016,2(33):106-110. [4] 葛祥丽,李慧敬,崔明湖,等. 艾司西酞普兰联合奥氮平治疗抑郁症的效果及安全性的Meta分析[J]. 四川精神卫生,2019,6(32):523-530. [5] 梁明明,李晓敏,曾超超. 焦点解决团体治疗的应用与展望[J]. 重庆医学,2017,9(46):3872-3874. [6] 世界卫生组织. 疾病和有关健康问题的国际统计分类(ICD-10)[M]. 2版. 北京: 人民卫生出版社, 1997: 287. [7] 刘联琦,周平,郝军锋,等. 精神分裂症抑郁症状的识别与诊断:四种抑郁量表的比较[J]. 神经疾病与精神卫生,2012,12(1):30-33. doi: 10.3969/j.issn.1009-6574.2012.01.010 [8] 张作记. 行为医学量表手册[M]. 北京: 中华医学电子音像出版社, 2005: 137-140, 187-188. [9] Sharry J. Solution focused group work[M]. London: Sage, 2001: 50-53. [10] 王红椿,曾保春. 焦点解决短期咨询在团体咨询中的应用[J]. 惠州学院学报(社会科学版),2008,28(2):84-87. [11] 戴艳,高翔,郑日昌. 焦点解决短期治疗(SFBT)的理论述评[J]. 心理科学,2004,27(6):1442-1445. doi: 10.3969/j.issn.1671-6981.2004.06.043 [12] 殷鹏,齐金蕾,刘韫宁. 2005-2017年中国疾病负担研究报告[J]. 中国循环杂志,2019,12(258):1145-1154. [13] Smith K. Mental health:a world of depression[J]. Nature,2014,515(7526):181. [14] Yue qin Huang,Yu Wang,Hong Wang. Prevalence of mental disorders in China:A cross-sectional epidemiological study[J]. Lancet Psychiatry,2019,2(10):1-13. [15] Aminnasaba,Mohammadis,Zarein-Ezhadm. Effectiveness of solution-focused brief therapy on depression and perceived stress in patients with breast cancer[J]. Tanaffos,2018,17(4):272-279. [16] 朱冬冬,李丽,杨永杰,等. 焦点解决治疗技术联合常规药物对青少年抑郁症患者的疗效[J]. 临床精神医学杂志,2021,31(4):291. doi: 10.3969/j.issn.1005-3220.2021.04.011 [17] 周勤,赵后锋,耿德勤,等. 焦点解决治疗技术联合常规药物与心理治疗对青少年重度抑郁症的效果研究[J]. 重庆医学,2021,16(50):2712-2720. [18] 史可,张桂芹,柳韦华. 焦点解决团体治疗的研究进展[J]. 循证护理,2021,7(58):1034-1040.